title: Effect of phosphodiesterase inhibitor-4, rolipram, on new bone formations by recombinant human bone morphogenetic protein-2.
abstract: Collagen sponge disks (6 mm diameter, 1 mm thickness) were impregnated with recombinant human bone morphogenetic protein-2 (rhBMP-2) (5 microg/disk) and implanted onto the back muscles of mice. Ten or 20 mg/kg per day of Rolipram, a selective inhibitory agent to phosphodiesterase type 4 (PDE-4), or vehicle, was injected subcutaneously into the host mice for 3 weeks. After treatment, rhBMP-2-induced ectopic ossicles were harvested and examined by radiographic and histologic methods to determine the size, bone quality, and mineral content of the ossicles. The ossicles from a group treated with 20 mg/kg per day Rolipram were significantly larger in size and higher in bone mineral density (BMD) and bone mineral content (BMC) than the control samples. No significant differences were noted in mice treated with 10 mg/kg per day of Rolipram. Histologically, ossicles from the high-dose (20 mg/kg per day) Rolipram-treated group showed densely packed, thicker trabeculae when compared with those from the control group. These experimental results indicate that the PDE-4 inhibitor, Rolipram, may enhance the bone-inducing capacity of BMP-2 in mesenchymal cells. This in turn may result in increased responsiveness to BMP-2 and point to a potential use of PDE-4 inhibitors for the promotion of rhBMP-dependent bone repair.
authors.affiliation: Department of Orthopaedic Surgery, Shinshu University School of Medicine, Nagano, Japan. horiuchi@hsp.md.shinshu-u.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Horiuchi
authors.forename: N
authors.initials: N
authors.lastname: Saito
authors.forename: T
authors.initials: T
authors.lastname: Kinoshita
authors.forename: S
authors.initials: S
authors.lastname: Wakabayashi
authors.forename: N
authors.initials: N
authors.lastname: Yotsumoto
authors.forename: K
authors.initials: K
authors.lastname: Takaoka
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D001842:Bone and Bones / Q000166:cytology; D008297:Male; D051379:Mice; D018482:Muscle, Skeletal; D015675:Osteocalcin / Q000097:blood; D010012:Osteogenesis / Q000187:drug effects*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D020889:Rolipram / Q000494:pharmacology*; D015503:Surgical Sponges; D016212:Transforming Growth Factor beta
chemical_list: C525718:BMP2 protein, human; C525719:Bmp2 protein, mouse; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D010726:Phosphodiesterase Inhibitors; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D015675:Osteocalcin; D020889:Rolipram